全文获取类型
收费全文 | 1719061篇 |
免费 | 128205篇 |
国内免费 | 4214篇 |
专业分类
耳鼻咽喉 | 22301篇 |
儿科学 | 56038篇 |
妇产科学 | 46675篇 |
基础医学 | 244983篇 |
口腔科学 | 49142篇 |
临床医学 | 153487篇 |
内科学 | 339376篇 |
皮肤病学 | 39544篇 |
神经病学 | 133008篇 |
特种医学 | 65258篇 |
外国民族医学 | 242篇 |
外科学 | 260782篇 |
综合类 | 39309篇 |
现状与发展 | 4篇 |
一般理论 | 545篇 |
预防医学 | 125265篇 |
眼科学 | 41024篇 |
药学 | 125964篇 |
7篇 | |
中国医学 | 4798篇 |
肿瘤学 | 103728篇 |
出版年
2021年 | 13691篇 |
2019年 | 14252篇 |
2018年 | 20813篇 |
2017年 | 15840篇 |
2016年 | 17457篇 |
2015年 | 20116篇 |
2014年 | 27555篇 |
2013年 | 39443篇 |
2012年 | 54949篇 |
2011年 | 57720篇 |
2010年 | 34157篇 |
2009年 | 31877篇 |
2008年 | 53142篇 |
2007年 | 56351篇 |
2006年 | 56636篇 |
2005年 | 53855篇 |
2004年 | 51825篇 |
2003年 | 49207篇 |
2002年 | 47288篇 |
2001年 | 92153篇 |
2000年 | 93925篇 |
1999年 | 77291篇 |
1998年 | 19891篇 |
1997年 | 17418篇 |
1996年 | 17514篇 |
1995年 | 16838篇 |
1994年 | 15387篇 |
1993年 | 14134篇 |
1992年 | 57550篇 |
1991年 | 55401篇 |
1990年 | 53087篇 |
1989年 | 50897篇 |
1988年 | 46258篇 |
1987年 | 45053篇 |
1986年 | 42328篇 |
1985年 | 40078篇 |
1984年 | 29438篇 |
1983年 | 24976篇 |
1982年 | 13959篇 |
1979年 | 25617篇 |
1978年 | 17629篇 |
1977年 | 14955篇 |
1976年 | 13906篇 |
1975年 | 14606篇 |
1974年 | 17666篇 |
1973年 | 16983篇 |
1972年 | 15701篇 |
1971年 | 14487篇 |
1970年 | 13465篇 |
1969年 | 12532篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
Kienbaum Peter Schaefer Maximilian S. Weibel Stephanie Schlesinger Tobias Meybohm Patrick Eberhart Leopold H. Kranke Peter 《Der Anaesthesist》2022,71(2):123-128
Die Anaesthesiologie - Auch wenn für Anästhesiologen über Jahrzehnte die Prophylaxe und Therapie postoperativer Schmerzen im Rahmen des postoperativen Patientenkomforts an vorderster... 相似文献
3.
4.
5.
6.
7.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
8.
9.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
10.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献